28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Characterizing subtle cognitive changes in preclinical Alzheimer's disease (AD) is difficult using traditional neuropsychological assessments. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Combinations of plasma and digital cognitive markers show promise for scalable diagnosis and prognosis of ADRD. 1 key finding →
Participants: 49 Evidence: low
Full summary, score breakdown and related studies → Original source
β-Amyloid plaques and tau-containing neurofibrillary tangles are the two neuropathological hallmarks of Alzheimer's disease (AD) and are thought to play crucial roles in a neurodegenerative cascade leading to dementia. 2 key findings →
Design: longitudinal study Participants: 32 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The medial temporal lobe (MTL) is an early site of tau accumulation and MTL dysfunction may underlie episodic-memory decline in aging and dementia. 4 key findings →
Design: longitudinal study Participants: 83 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The goal of this paper was to evaluate the in vivo kinetics of the novel tau-specific PET radioligand 18 F-AV-1451 in cognitively healthy control (HC) and Alzheimer disease (AD) subjects, using reference region analyses. 2 key findings →
Design: longitudinal study Participants: 43 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Identifying high-risk populations is an important component of disease prevention strategies. 2 key findings →
Design: longitudinal study Participants: 100 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The FBB threshold based on the young sample (1.08; 18 CL) was consistent with that of the data-driven approach (1.10; 21 CL), and the existing FBP threshold converted to CL with the derived transformation (1.11; 20 CL). 3 key findings →
Design: cross-sectional Participants: 62 Evidence: moderate
Full summary, score breakdown and related studies → Original source
While aggregation of neuroimaging datasets from multiple sites and scanners can yield increased statistical power, it also presents challenges due to systematic scanner effects. 5 key findings →
Design: cross-sectional Participants: 663 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in ageing, affecting around 46 million people worldwide but few treatments are currently available. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Current approaches to the early detection of Alzheimer's disease (AD) rely upon classifying individuals as "positive" or "negative" for biomarkers related to the core pathology of β-amyloid (Aβ). 5 key findings →
Design: longitudinal study Participants: 71 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Use of metformin, DPP4 inhibitors, GLP1 analogs and SGLT2 inhibitors was associated with lower risk of dementia in patients with diabetes. 3 key findings →
Design: case-control study Participants: 250 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The 2020 pipeline has innovations in clinical trials and treatment targets that provide hope for greater success in AD drug development programs. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is associated with severe cognitive impairments as well as some metabolic defects. 5 key findings →
Participants: 30 Evidence: high
Full summary, score breakdown and related studies → Original source
Lower RBC DHA levels are associated with smaller brain volumes and a "vascular" pattern of cognitive impairment even in persons free of clinical dementia. 3 key findings →
Design: cross-sectional Participants: 1,575 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Social frailty is associated with physical functioning, cognition, and depression, and predicts mortality. 3 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Sensory impairments are associated with greater risk of dementia in Chinese older adults. 4 key findings →
Design: cross-sectional Participants: 250,752 Evidence: low
Full summary, score breakdown and related studies → Original source
Depression symptoms before the onset of AD are associated with the development of AD, even in families where first depression symptoms occurred more than 25 years before the onset of AD. 4 key findings →
Design: case-control study Participants: 1,953 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Long-term exposure to the highest tertile of PM10 or ozone was significantly associated with an increased risk of AD and VaD. 2 key findings →
Design: case-control study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Much can still be done in the way of service development and provision, GP training and education, and the eradication of stigma attached to dementia, to improve the early detection and management of dementia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
More than one third of severely cognitively impaired residents in US nursing homes have feeding tubes. 5 key findings →
Design: cross-sectional Participants: 186,835 Evidence: low
Full summary, score breakdown and related studies → Original source
Key neuropathological changes associated with late-onset dementia are not fully understood. 3 key findings →
Design: longitudinal study Participants: 213 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Using 12-year longitudinal data from deceased participants of the Berlin Aging Study (N = 414; age 70-103 years, at first occasion; M = 87 years, SD = 8.13), the authors examined whether and how old and very old individuals exhibit terminal decline in reported life satisfaction at the end of life. 2 key findings →
Design: longitudinal study Participants: 414 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Patients with BP are more likely to have various neurological diseases, schizophrenia and psoriasis prior to the diagnosis of BP, supporting associations found in other studies. 3 key findings →
Design: case-control study Participants: 3,485 Evidence: moderate
Full summary, score breakdown and related studies → Original source
An increased incidence of mild cognitive impairment was observed in community-dwelling elderly adults who had nonpsychotic psychiatric symptoms at baseline. 3 key findings →
Design: cohort study Participants: 365 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Neuropsychiatric symptoms are common features of MCI. 1 key finding →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →